Abstract:CD4 mimics are small molecules that inhibit the interaction of gp120 with CD4. We have developed several CD4 mimics. Herein, hybrid molecules consisting of CD4 mimics with a long alkyl chain or a PEG unit attached through a self-cleavable linker were synthesized. In anti-HIV activity, modification with a PEG unit appeared to be more suitable than modification with a long alkyl chain. Thus, hybrid molecules of CD4 mimics, with PEG units attached through an uncleavable linker, were developed and showed high anti-HIV activity and low cytotoxicity. In investigation of pharmacokinetics in a rhesus macaque, a hybrid compound had a more effective PK profile than that of the parent compound, and intramuscular injection was a more useful administration route to maintain the high blood concentration of the CD4 mimic than intravenous injection. The presented hybrid molecules of CD4 mimics with a PEG unit would be practically useful when combined with a neutralizing antibody.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01153?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01153</a>.Experimental procedures of compound synthesis including characterization data, a calibration curve of YIR-821·2TFA used to calculate PK in a rhesus macaque, degradation experiments of the hybrid molecule 45 in the PBS solution (pH 7.4) at 37 °C, a calibration curve of the hybrid molecule 58·2TFA used to calculate PK in a rhesus macaque by iv injection, a calibration curve of 58·2TFA used to calculate PK in a rhesus macaque by im injection, the structures of YIR-821 and compound 58 docked in gp120, HPLC analysis of evaluation of the biological stability of compound 58·2TFA treated with human liver microsomes, FACS analysis of EGFP and HIV-1 JR-FL envelope (Env) expressing HEK293T cells treated with anti-CD4i antibodies, and inhibition of gp120-CD4 binding by compound 58 and YIR-821 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_001.pdf">PDF</a>)Molecular formula strings of 2–22, 24, 30, 32, 35, 36, 38–46, 49, 50, 54, 58, and 62 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

A minimally cytotoxic CD4 mimic as an HIV entry inhibitor

Soluble-type small-molecule CD4 mimics as HIV entry inhibitors

Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors

Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors

Flexibility of small molecular CD4 mimics as HIV entry inhibitors

Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates

Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors

Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4

N-Phenyl-N'-(2,2,6,6-Tetramethyl-Piperidin-4-Yl)-Oxalamides As A New Class Of Hiv-1 Entry Inhibitors That Prevent Gp120 Binding To Cd4

In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

A Novel CXCR4 Targeting Protein SDF-1/54 As an HIV-1 Entry Inhibitor.

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Identification of a D-Amino Acid Decapeptide HIV-1 Entry Inhibitor

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein

Synthesis, Biological Evaluation and Molecular Docking Study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide Derivatives As Potent HIV-1 Vif Antagonists.

A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.

VIRTUAL SCREENING AND IDENTIFICATION OF POTENTIAL HIV-1 INHIBITORS BASED ON THE CROSS-REACTIVE NEUTRALIZING ANTIBODY N6